-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, AVrbTrxbcF01elQWZGEVYqJE60uya8QHJAl4dQr4VTFF9WUMZpR9vRU/sziYVguI PZdizkTDzlU0XeIuaMDaig== 0000950156-11-000024.txt : 20110214 0000950156-11-000024.hdr.sgml : 20110214 20110214184644 ACCESSION NUMBER: 0000950156-11-000024 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20110214 DATE AS OF CHANGE: 20110214 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: IGI LABORATORIES, INC CENTRAL INDEX KEY: 0000352998 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 010355758 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-34057 FILM NUMBER: 11609552 BUSINESS ADDRESS: STREET 1: 105 LINCOLN AVENUE CITY: BUENA STATE: NJ ZIP: 08310 BUSINESS PHONE: 6096971441 MAIL ADDRESS: STREET 1: 105 LINCOLN AVENUE CITY: BUENA STATE: NJ ZIP: 08310 FORMER COMPANY: FORMER CONFORMED NAME: IGI INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: IMMUNOGENETICS INC DATE OF NAME CHANGE: 19870814 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: IGI LABORATORIES, INC CENTRAL INDEX KEY: 0000352998 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 010355758 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 105 LINCOLN AVENUE CITY: BUENA STATE: NJ ZIP: 08310 BUSINESS PHONE: 6096971441 MAIL ADDRESS: STREET 1: 105 LINCOLN AVENUE CITY: BUENA STATE: NJ ZIP: 08310 FORMER COMPANY: FORMER CONFORMED NAME: IGI INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: IMMUNOGENETICS INC DATE OF NAME CHANGE: 19870814 SC 13G/A 1 d76151_igi13ga.htm BODY OF SC 13G/A Converted by EDGARwiz



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


SCHEDULE 13G

(Rule 13d-102)



Information To Be Included In Statements Filed Pursuant

To Rules 13d-1(b), (c), and (d) and Amendments Thereto Filed

Pursuant To Rule 13d-2


(Amendment No. 15)*


IGI Laboratories, Inc.

(Name of Company)


Common Stock

(Title of Class of Securities)


449575 10 9

(CUSIP Number)


December 31, 2010

(Date of Event Which Requires Filing of This Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:


[   ]

Rule 13d-1(b)


[X]

Rule 13d-1(c)


[   ]

Rule 13d-1(d)




______________

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.


The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).








CUSIP No. 449575 10 9

                    SCHEDULE 13G

1

NAME OF REPORTING PERSON


Jane E. Hager

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

 

 

(a) [   ]

(b) [   ]

3

SEC USE ONLY

4

CITIZENSHIP OR PLACE OF ORGANIZATION


United States of America

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5

SOLE VOTING POWER


902,458

6

SHARED VOTING POWER


2,527,405

7

SOLE DISPOSITIVE POWER


902,458

8

SHARED DISPOSITIVE POWER


2,527,405

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON


3,429,863

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

 

[   ]

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9


8.70%

12

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)


IN









CUSIP No. 449575 10 9

                    SCHEDULE 13G

1

NAME OF REPORTING PERSON


Edward B. Hager

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

 

 

(a) [   ]

(b) [   ]

3

SEC USE ONLY

4

CITIZENSHIP OR PLACE OF ORGANIZATION


United States of America

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5

SOLE VOTING POWER


0

6

SHARED VOTING POWER


2,674,816

7

SOLE DISPOSITIVE POWER


0

8

SHARED DISPOSITIVE POWER


2,674,816

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON


2,674,816

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

 

[   ]

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9


6.80%

12

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)


IN









CUSIP No. 449575 10 9

                    SCHEDULE 13G

1

NAME OF REPORTING PERSON


Hager Family Trust

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

 

 

(a) [   ]

(b) [   ]

3

SEC USE ONLY

4

CITIZENSHIP OR PLACE OF ORGANIZATION


New Hampshire

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5

SOLE VOTING POWER


1,307,893

6

SHARED VOTING POWER


0

7

SOLE DISPOSITIVE POWER


1,307,893

8

SHARED DISPOSITIVE POWER


0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON


1,307,893

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

 

[   ]

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9


3.33%

12

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)


OO








This Amendment No. 15 to Schedule 13G amends and restates Amendment No. 14 to Schedule 13G filed by each of Jane E. Hager and Edward B. Hager with the Securities and Exchange Commission on February 17, 2009, respectively.


Item 1(a)

Name of Company.


IGI Laboratories, Inc., a Delaware corporation (the “Company”)

 

 

Item 1(b)

Address of Company’s Principal Executive Offices.


105 Lincoln Avenue

Buena, New Jersey 08310

 

 

Item 2(a)

Name of Person Filing.


Jane E. Hager

Edward B. Hager

Hager Family Trust


The foregoing persons are sometimes individually referred to herein as a “Reporting Person” and collectively as the “Reporting Persons.”

 

 

Item 2(b)

Address of Principal Business Office or, if none, Residence.


The address of the principal business offices of each of the Reporting Persons is c/o IGI Laboratories, Inc., 105 Lincoln Avenue, Buena, New Jersey 08310.

 

 

Item 2(c)

Citizenship.


Each of Mr. and Mrs. Hager is a citizen of the United States of America.

The place of organization of the Hager Family Trust is New Hampshire.

 

 

Item 2(d)

Title of Class of Securities.


Common Stock, $0.01 par value per share (the “Common Stock”)

 

 

Item 2(e)

CUSIP Number.


449575 10 9

 

 

Item 3

If this Statement is Filed pursuant to Rules 13d-1(b), or 13d-2(b), Check whether the Person Filing is a:

 

 

 

 

(a) [_]

Broker or dealer registered under Section 15 of the Exchange Act

 

 

 

 

(b) [_]

Bank as defined in Section 3(a)(6) of the Exchange Act

 

 

 

 

(c) [_]

Insurance company as defined in Section 3(a)(19) of the Exchange Act








 

(d) [_]

Investment company registered under Section 8 of the Investment Company Act

 

 

 

 

(e) [_]

An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E)

 

 

 

 

(f) [_]

An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F)

 

 

 

 

(g) [_]

A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G)

 

 

 

 

(h) [_]

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act

 

 

 

 

(i) [_]

A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act

 

 

 

 

(j) [_]

A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J)

 

 

 

 

(k) [_]

Group, in accordance with Rule 13d-1(b)(1)(ii)(J)

 

 

Item 4

Ownership.


Provide the following information regarding the aggregate number and percentage of the class of securities of the Company identified in Item 1.

(a)    Amount beneficially owned:

        (1)   As of February 10, 2011, Jane E. Hager beneficially owned 3,429,863 shares of Common Stock of the Company, which includes the following:

(i)   22,411 shares of Common Stock were held directly by Mrs. Hager;

(ii)   678,830 shares of Common Stock were held by the Jane E. Hager Trust of 1990 of which Mrs. Hager acts as sole trustee and has sole voting and dispositive power over the shares held by the trust and retains the power to revoke the trust;

(iii)  125,000 shares of Common Stock purchasable upon exercise of stock options exercisable within 60 days of February 10, 2011;

(iv)  1,307,893 shares of Common Stock were held by the Hager Family Trust of which Mrs. Hager serves as co-trustee with Edward B. Hager, her husband, and shares voting and dispositive power over the shares held by the trust with her husband;








 

(v)   72,464 shares of common stock issuable upon conversion of 50 shares of Series C Convertible Preferred Stock held by Jane E. Hager Trust of 1990 of  which Mrs. Hager Acts as sole trustee and has sole voting and dispositive power of the shares held by the trust and 3,753 shares of common stock issuable upon conversion of accrued and unpaid dividends on the Series C Convertible Preferred Stock from the issuance date of such shares through April 11, 2011; and

(vi)  1,219,512 shares of Common Stock held by Pinnacle Mountain Partners, LLC of which Mrs. Hager and her husband share voting and investment power.

 

 

 

        (2)   As of February 10, 2011, Edward B. Hager beneficially owned an aggregate of 2,674,816 shares of Common Stock of the Company, which includes the following:

(i)   1,307,893 shares of Common Stock which were held by the Hager Family Trust of which Mr. Hager serves as co-trustee with his wife, Jane E. Hager, and shares voting and dispositive power over the shares held by the trust with his wife;

(ii)  22,411 shares of Common Stock held by his wife;

(iii) 125,000 shares of Common Stock purchasable upon exercise of stock options exercisable within 60 days of February 10, 2011 by his wife; and

(iv)  1,219,512 shares of Common Stock held by Pinnacle Mountain Partners, LLC of which Mr. Hager and his wife share voting and investment power.

        (3)   As of February 10, 2011, the Hager Family Trust beneficially owned an aggregate of 1,307,893 shares of Common Stock of the Company.  Jane E. Hager and Edward B. Hager are co-trustees of the Hager Family Trust and share voting and dispositive power over the shares held by the trust.  Mr. Hager is the settler of the trust and retains the power to revoke the trust.  Mrs. Hager is the sole beneficiary of the Hager Family Trust.

By virtue of their marital status, each of Mr. and Mrs. Hager is considered to have the power to vote or direct the vote of, and to dispose or direct the disposition of, the shares of the Company’s Common Stock owned by each other, for his or her account. Where Mrs. Hager acts as sole trustee of a trust, the sole trustee is considered to have the power to vote or direct the vote of, and to dispose or direct the disposition of, the shares of the Company’s Common Stock owned by the trust, but the trustee’s spouse is not considered to have or share such power.








 

The filing of this statement shall not be construed as an admission that each of the Reporting Persons is, for the purposes of Sections 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended, the beneficial owner of any securities covered by this statement.

(b)    Percent of class:  See Item 11 of the Cover Page of this Schedule 13G for each of the Reporting Persons.

(c)    Number of shares as to which the person has:

(i)   Sole power to vote or to direct the vote:  See Item 5 of the Cover Page of this Schedule 13G for each of the Reporting Persons.

(ii)  Shared power to vote or to direct the vote: See Item 6 of the Cover Page of this Schedule 13G for each of the Reporting Persons.

(iii) Sole power to dispose or to direct the disposition of: See Item 7 of the Cover Page of this Schedule 13G for each of the Reporting Persons.

(iv)  Shared power to dispose or to direct the disposition of: See Item 8 of the Cover Page of this Schedule 13G for each of the Reporting Persons.

 

 

Item 5

Ownership of Five Percent or Less of a Class.


If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [   ].

 

 

Item 6

Ownership of More than Five Percent on Behalf of Another Person.


Not applicable.

 

 

Item 7

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.


Not applicable.

 

 

Item 8

Identification and Classification of Members of the Group.


Not applicable.

 

 

Item 9

Notice of Dissolution of Group.


Not applicable.








Item 10

Certification.


By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.







SIGNATURE


After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Date: February 14, 2011

 

/s/ Jane E. Hager

 

Jane E. Hager

 

 

 

/s/ Edward B. Hager

 

Edward B. Hager

 

 

 

Hager Family Trust

 

 

 

By:

/s/ Edward B. Hager

 

Edward B. Hager, as trustee








EXHIBIT INDEX


Exhibit 1.     Joint Filing Agreement







Exhibit 1


Joint Filing Agreement


The undersigned hereby agree that the statement on Amendment No. 15 to Schedule 13G, dated as of the date hereof (the “Statement”), with respect to the common stock, $0.01 par value per share, of IGI Laboratories, Inc., a Delaware corporation, is, and any amendments thereto executed by each of us shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934, as amended, and that this Joint Filing Agreement shall be included as an exhibit to the Statement and each such amendment.  Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning itself contained therein.  This Joint Filing Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument .


IN WITNESS WHEREOF, the undersigned have executed this Joint Filing Agreement as of the 14th day of February, 2011.


/s/ Jane E. Hager

Jane E. Hager




/s/ Edward B. Hager

Edward B. Hager



Hager Family Trust



By:  /s/ Edward B. Hager

Edward B. Hager, as trustee






-----END PRIVACY-ENHANCED MESSAGE-----